JP2015518892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518892A5 JP2015518892A5 JP2015516145A JP2015516145A JP2015518892A5 JP 2015518892 A5 JP2015518892 A5 JP 2015518892A5 JP 2015516145 A JP2015516145 A JP 2015516145A JP 2015516145 A JP2015516145 A JP 2015516145A JP 2015518892 A5 JP2015518892 A5 JP 2015518892A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- iii
- item
- contacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 36
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 14
- 239000003054 catalyst Substances 0.000 claims description 10
- 229910052751 metal Inorganic materials 0.000 claims description 10
- 239000002184 metal Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000011065 in-situ storage Methods 0.000 claims description 8
- 239000011541 reaction mixture Substances 0.000 claims description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 8
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- CEFVHPDFGLDQKU-YFKPBYRVSA-N (2s)-2-(methoxycarbonylamino)-3-methylbutanoic acid Chemical compound COC(=O)N[C@@H](C(C)C)C(O)=O CEFVHPDFGLDQKU-YFKPBYRVSA-N 0.000 claims description 6
- MDNDJMCSXOXBFZ-UHFFFAOYSA-N 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane Chemical compound O1CC(C)(C)COB1B1OCC(C)(C)CO1 MDNDJMCSXOXBFZ-UHFFFAOYSA-N 0.000 claims description 6
- 101150003085 Pdcl gene Proteins 0.000 claims description 6
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical group O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 claims description 6
- BWILYWWHXDGKQA-UHFFFAOYSA-M potassium propanoate Chemical group [K+].CCC([O-])=O BWILYWWHXDGKQA-UHFFFAOYSA-M 0.000 claims description 6
- 235000010332 potassium propionate Nutrition 0.000 claims description 6
- 239000004331 potassium propionate Substances 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical group CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 4
- 235000006408 oxalic acid Nutrition 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 4
- 235000011009 potassium phosphates Nutrition 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 125000006242 amine protecting group Chemical group 0.000 claims description 3
- ALLIZEAXNXSFGD-UHFFFAOYSA-N 1-methyl-2-phenylbenzene Chemical compound CC1=CC=CC=C1C1=CC=CC=C1 ALLIZEAXNXSFGD-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000000732 arylene group Chemical group 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- USVZFSNDGFNNJT-UHFFFAOYSA-N cyclopenta-1,4-dien-1-yl(diphenyl)phosphane (2,3-dichlorocyclopenta-1,4-dien-1-yl)-diphenylphosphane iron(2+) Chemical group [Fe++].c1cc[c-](c1)P(c1ccccc1)c1ccccc1.Clc1c(cc[c-]1Cl)P(c1ccccc1)c1ccccc1 USVZFSNDGFNNJT-UHFFFAOYSA-N 0.000 claims description 2
- BSHICDXRSZQYBP-UHFFFAOYSA-N dichloromethane;palladium(2+) Chemical compound [Pd+2].ClCCl BSHICDXRSZQYBP-UHFFFAOYSA-N 0.000 claims description 2
- GPVWUKXZFDHGMZ-UHFFFAOYSA-N dicyclohexyl-[2-(2-methylphenyl)phenyl]phosphane Chemical group CC1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 GPVWUKXZFDHGMZ-UHFFFAOYSA-N 0.000 claims description 2
- 150000004820 halides Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 238000005580 one pot reaction Methods 0.000 claims description 2
- 150000003891 oxalate salts Chemical class 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- ZVEBIERALJAHTN-QTPDGVKASA-N CC(C)(C)OC(N(CC1(CC1)C1)C1c1ncc(-c(cc2)cc(C(c3c4)(F)F)c2-c3ccc4-c(cc2)cc3c2nc(C([C@@H]2CC4CC2)N4C(OC(C)(C)C)=O)[nH]3)[nH]1)=O Chemical compound CC(C)(C)OC(N(CC1(CC1)C1)C1c1ncc(-c(cc2)cc(C(c3c4)(F)F)c2-c3ccc4-c(cc2)cc3c2nc(C([C@@H]2CC4CC2)N4C(OC(C)(C)C)=O)[nH]3)[nH]1)=O ZVEBIERALJAHTN-QTPDGVKASA-N 0.000 description 2
- 0 *N(CC1(CC1)C1)[C@@]1c1ncc(-c(cc2)cc(C(c3c4)(F)F)c2-c3ccc4-c(cc2)cc3c2nc(C2N(*)C4C[C@]2CC4)[n]3)[n]1 Chemical compound *N(CC1(CC1)C1)[C@@]1c1ncc(-c(cc2)cc(C(c3c4)(F)F)c2-c3ccc4-c(cc2)cc3c2nc(C2N(*)C4C[C@]2CC4)[n]3)[n]1 0.000 description 1
- SXHIRKANGZPOLR-UHFFFAOYSA-N Bc(cc1)cc2c1nc(C(C1CC3CC1)N3C(OC(C)(C)C)=O)[nH]2 Chemical compound Bc(cc1)cc2c1nc(C(C1CC3CC1)N3C(OC(C)(C)C)=O)[nH]2 SXHIRKANGZPOLR-UHFFFAOYSA-N 0.000 description 1
- ZTUIEXAOZBOBBC-SUHMBNCMSA-N CC(C)(C)OC(N(CC1(CC1)C1)[C@@H]1c1ncc(-c(cc2)cc(C(CC=C)(c3c4)F)c2-c3ccc4Br)[nH]1)=O Chemical compound CC(C)(C)OC(N(CC1(CC1)C1)[C@@H]1c1ncc(-c(cc2)cc(C(CC=C)(c3c4)F)c2-c3ccc4Br)[nH]1)=O ZTUIEXAOZBOBBC-SUHMBNCMSA-N 0.000 description 1
- CEFVHPDFGLDQKU-UHFFFAOYSA-N CC(C)C(C(O)=O)NC(OC)=O Chemical compound CC(C)C(C(O)=O)NC(OC)=O CEFVHPDFGLDQKU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261655935P | 2012-06-05 | 2012-06-05 | |
| US61/655,935 | 2012-06-05 | ||
| US13/800,202 | 2013-03-13 | ||
| US13/800,202 US9056860B2 (en) | 2012-06-05 | 2013-03-13 | Synthesis of antiviral compound |
| PCT/US2013/044148 WO2013184702A1 (en) | 2012-06-05 | 2013-06-04 | Synthesis of antiviral compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017116558A Division JP6356876B2 (ja) | 2012-06-05 | 2017-06-14 | 抗ウイルス化合物の合成 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015518892A JP2015518892A (ja) | 2015-07-06 |
| JP2015518892A5 true JP2015518892A5 (enExample) | 2016-07-28 |
| JP6181169B2 JP6181169B2 (ja) | 2017-08-16 |
Family
ID=49671039
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516145A Active JP6181169B2 (ja) | 2012-06-05 | 2013-06-04 | 抗ウイルス化合物の合成 |
| JP2017116558A Active JP6356876B2 (ja) | 2012-06-05 | 2017-06-14 | 抗ウイルス化合物の合成 |
| JP2018113637A Active JP6594487B2 (ja) | 2012-06-05 | 2018-06-14 | 抗ウイルス化合物の合成 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017116558A Active JP6356876B2 (ja) | 2012-06-05 | 2017-06-14 | 抗ウイルス化合物の合成 |
| JP2018113637A Active JP6594487B2 (ja) | 2012-06-05 | 2018-06-14 | 抗ウイルス化合物の合成 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9056860B2 (enExample) |
| EP (1) | EP2855454B1 (enExample) |
| JP (3) | JP6181169B2 (enExample) |
| KR (2) | KR20200066376A (enExample) |
| CN (2) | CN107266428A (enExample) |
| AU (1) | AU2013271772B2 (enExample) |
| BR (1) | BR112014030365A2 (enExample) |
| CA (1) | CA2875508C (enExample) |
| ES (1) | ES2587782T3 (enExample) |
| HK (2) | HK1209124A1 (enExample) |
| IL (2) | IL235941B (enExample) |
| IN (1) | IN2014MN02496A (enExample) |
| MX (1) | MX350892B (enExample) |
| PT (1) | PT2855454T (enExample) |
| RU (1) | RU2636943C2 (enExample) |
| SG (1) | SG11201408011SA (enExample) |
| WO (1) | WO2013184702A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI2604620T4 (fi) | 2003-05-30 | 2024-09-11 | Gilead Pharmasset Llc | Modifioituja fluorinoituja nukleosidianalogeja |
| KR101991298B1 (ko) | 2011-09-16 | 2019-06-21 | 길리애드 파마셋 엘엘씨 | Hcv 치료 방법 |
| US8969588B2 (en) * | 2012-06-05 | 2015-03-03 | Gilead Pharmasset Llc | Solid forms of an antiviral compound |
| US9056860B2 (en) | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
| HUE047777T2 (hu) | 2013-01-31 | 2020-05-28 | Gilead Pharmasset Llc | Két vírusellenes vegyület kombinációs készítménye |
| CN104211565A (zh) * | 2013-05-31 | 2014-12-17 | 浙江九洲药业股份有限公司 | 一种抗丙型肝炎药物中间体的制备方法 |
| EP4005560A1 (en) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| EP2883876A1 (en) * | 2013-12-16 | 2015-06-17 | Actelion Pharmaceuticals Ltd. | Stereoselective synthesis of substituted pyrrolidines |
| TW202014413A (zh) | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| CN104513223B (zh) * | 2014-11-20 | 2017-07-14 | 上海众强药业有限公司 | 芴乙酮衍生物的制备方法 |
| CN104513147B (zh) * | 2014-11-20 | 2016-05-11 | 上海众强药业有限公司 | 芴乙酮衍生物的制备方法 |
| US20180009790A1 (en) * | 2014-12-24 | 2018-01-11 | Prasad Raju Vnkv Vetukuri | An improved process for the preparation of hcv inhibitor |
| CN104530016A (zh) * | 2014-12-25 | 2015-04-22 | 上海泓博智源医药技术有限公司 | 一种雷迪帕韦的制备方法及其中间体 |
| CN107427495A (zh) | 2015-02-13 | 2017-12-01 | 桑多斯股份公司 | 包含雷迪帕韦和索非布韦的药物组合物 |
| WO2016145269A1 (en) | 2015-03-12 | 2016-09-15 | Teva Pharmaceuticals International Gmbh | Solid state forms ledipasvir and processes for preparation of ledipasvir |
| CN104829599B (zh) * | 2015-03-17 | 2017-06-09 | 上海众强药业有限公司 | 雷迪帕韦及其衍生物的制备方法及用于制备雷迪帕韦的中间体化合物 |
| CN104788361B (zh) * | 2015-04-21 | 2017-06-30 | 杭州科巢生物科技有限公司 | 5‑氮杂螺[2.4]庚烷‑6‑甲酸衍生物的合成方法 |
| WO2016199049A1 (en) * | 2015-06-09 | 2016-12-15 | Hetero Research Foundation | Process for the preparation of ledipasvir |
| CN104926796A (zh) * | 2015-06-17 | 2015-09-23 | 南通常佑药业科技有限公司 | 一种新的ns5a抑制剂药物的制备方法 |
| WO2016207915A1 (en) * | 2015-06-26 | 2016-12-29 | Mylan Laboratories Limited | Process for the preparation of ledipasvir |
| CN105017228A (zh) * | 2015-07-03 | 2015-11-04 | 上海众强药业有限公司 | 一种雷迪帕韦中间体单硫酸盐、其晶型及其制备方法 |
| CN104961733B (zh) * | 2015-07-06 | 2019-04-09 | 上海众强药业有限公司 | 雷迪帕韦晶型及其制备方法 |
| KR101919194B1 (ko) * | 2015-09-15 | 2018-11-15 | 주식회사 엘지화학 | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 |
| CN105237516B (zh) * | 2015-10-13 | 2018-01-02 | 厦门市蔚嘉化学科技有限公司 | 一种雷迪帕韦的制备方法 |
| CN105399657B (zh) * | 2015-10-21 | 2017-10-10 | 海门慧聚药业有限公司 | 雷迪帕韦关键中间体的制备 |
| WO2017072596A1 (en) * | 2015-10-26 | 2017-05-04 | Optimus Drugs (P) Ltd | An improved process for the preparation of ledipasvir |
| CN105237384B (zh) * | 2015-11-06 | 2017-06-30 | 上海万溯化学有限公司 | 一种多取代芴衍生物的制备方法 |
| CN106892905A (zh) * | 2015-12-17 | 2017-06-27 | 常州市勇毅生物药业有限公司 | 一种雷迪帕韦的制备方法 |
| US20190062332A1 (en) * | 2016-02-01 | 2019-02-28 | Lupin Limited | Process for the preparation of ledipasvir and intermediates thereof |
| WO2017145028A1 (en) * | 2016-02-26 | 2017-08-31 | Glenmark Pharmaceuticals Limited | Process for preparation of ledipasvir |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017195147A1 (en) | 2016-05-12 | 2017-11-16 | Lupin Limited | Process for the preparation of ledipasvir and intermediates thereof |
| CN106008316B (zh) * | 2016-06-17 | 2018-04-27 | 成都百事兴科技实业有限公司 | 一种合成雷迪帕韦手性中间体的方法 |
| CN105968040B (zh) * | 2016-06-29 | 2019-02-05 | 爱斯特（成都）生物制药股份有限公司 | 一种雷迪帕韦中间体的制备方法 |
| CN107641081A (zh) * | 2016-07-22 | 2018-01-30 | 江苏威凯尔医药科技有限公司 | 一种药物中间体的制备方法 |
| CN106349229B (zh) * | 2016-08-25 | 2018-11-06 | 安徽华昌高科药业有限公司 | 雷迪帕韦中间体的制备方法及中间体化合物 |
| CN106632275B (zh) * | 2016-12-20 | 2018-03-06 | 上海同昌生物医药科技有限公司 | 一种雷迪帕韦的制备方法及制备雷迪帕韦的中间体 |
| US10392370B2 (en) | 2017-03-13 | 2019-08-27 | Optimus Drugs Pvt Ltd | Process for the preparation of Daclatasvir dihydrochloride and its intermediates |
| CN107488685A (zh) * | 2017-06-13 | 2017-12-19 | 南京方生和医药科技有限公司 | (s)‑5‑氮杂螺环[2.4]庚烷‑6‑羧酸及其衍生物的酶化学制备方法 |
| EP3641762A4 (en) | 2017-06-20 | 2021-03-10 | C4 Therapeutics, Inc. | N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION |
| CN107954990A (zh) * | 2017-11-14 | 2018-04-24 | 安徽诺全药业有限公司 | 一种雷迪帕维的制备方法 |
| CN107879908A (zh) * | 2017-11-14 | 2018-04-06 | 安徽诺全药业有限公司 | 一种雷迪帕维关键中间体及其制备方法 |
| CN108753863A (zh) * | 2018-06-14 | 2018-11-06 | 慎终（上海）生物科技有限公司 | 雷迪帕韦中间体的合成工艺 |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| EP3636637A1 (en) * | 2018-10-10 | 2020-04-15 | Forma Therapeutics, Inc. | Inhibiting fatty acid synthase (fasn) |
| EP3885339A1 (en) * | 2020-03-27 | 2021-09-29 | Rottapharm Biotech S.r.l. | Process for the preparation of (r)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof |
| CN112851545B (zh) * | 2020-07-08 | 2022-09-20 | 日照巴洛特药业有限公司 | 一种雷迪帕韦中间体的合成工艺 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001051919A2 (en) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| US7759337B2 (en) * | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| TWI410422B (zh) * | 2007-01-15 | 2013-10-01 | Mitsubishi Tanabe Pharma Corp | 縮合四氫喹啉衍生物及其醫藥用途 |
| NZ587557A (en) * | 2008-02-13 | 2012-04-27 | Bristol Myers Squibb Co | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors |
| US8232409B2 (en) * | 2008-10-15 | 2012-07-31 | Janssen Pharmaceutica N.V. | Heterocyclic benzimidazoles as TRPM8 modulators |
| LT2873665T (lt) | 2009-05-13 | 2016-10-25 | Gilead Pharmasset Llc | Antivirusiniai junginiai |
| EP2475256A4 (en) * | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US9296698B2 (en) * | 2009-11-23 | 2016-03-29 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| WO2011156757A1 (en) | 2010-06-10 | 2011-12-15 | Gilead Sciences, Inc. | Combination of anti-hcv compounds with ribavirin for the treatment of hcv |
| US8969588B2 (en) | 2012-06-05 | 2015-03-03 | Gilead Pharmasset Llc | Solid forms of an antiviral compound |
| US9056860B2 (en) * | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
-
2013
- 2013-03-13 US US13/800,202 patent/US9056860B2/en active Active
- 2013-06-04 MX MX2014014569A patent/MX350892B/es active IP Right Grant
- 2013-06-04 HK HK15109928.1A patent/HK1209124A1/xx unknown
- 2013-06-04 SG SG11201408011SA patent/SG11201408011SA/en unknown
- 2013-06-04 AU AU2013271772A patent/AU2013271772B2/en active Active
- 2013-06-04 ES ES13729208.2T patent/ES2587782T3/es active Active
- 2013-06-04 CN CN201710524415.2A patent/CN107266428A/zh active Pending
- 2013-06-04 PT PT137292082T patent/PT2855454T/pt unknown
- 2013-06-04 IN IN2496MUN2014 patent/IN2014MN02496A/en unknown
- 2013-06-04 CN CN201380029806.7A patent/CN104520293B/zh active Active
- 2013-06-04 RU RU2014150435A patent/RU2636943C2/ru not_active IP Right Cessation
- 2013-06-04 BR BR112014030365A patent/BR112014030365A2/pt active Search and Examination
- 2013-06-04 JP JP2015516145A patent/JP6181169B2/ja active Active
- 2013-06-04 WO PCT/US2013/044148 patent/WO2013184702A1/en not_active Ceased
- 2013-06-04 EP EP13729208.2A patent/EP2855454B1/en active Active
- 2013-06-04 KR KR1020207015492A patent/KR20200066376A/ko not_active Ceased
- 2013-06-04 CA CA2875508A patent/CA2875508C/en active Active
- 2013-06-04 KR KR1020147036884A patent/KR102206434B1/ko active Active
-
2014
- 2014-11-27 IL IL235941A patent/IL235941B/en not_active IP Right Cessation
-
2015
- 2015-05-05 US US14/704,627 patent/US20150232453A1/en not_active Abandoned
- 2015-10-12 HK HK18104959.1A patent/HK1245273A1/zh unknown
-
2016
- 2016-08-04 US US15/228,825 patent/US9718807B2/en active Active
-
2017
- 2017-06-14 JP JP2017116558A patent/JP6356876B2/ja active Active
-
2018
- 2018-03-25 IL IL258327A patent/IL258327A/en unknown
- 2018-06-14 JP JP2018113637A patent/JP6594487B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015518892A5 (enExample) | ||
| RU2014150435A (ru) | Получение антивирусного соединения | |
| Hashmi et al. | Gold-catalyzed addition of X–H bonds to C–C multiple bonds | |
| Xie et al. | (NHC) Cu-catalyzed mild C–H amidation of (hetero) arenes with deprotectable carbamates: scope and mechanistic studies | |
| JP2022043078A5 (enExample) | ||
| JP7043488B2 (ja) | クロスカップリング方法 | |
| JP2011508726A5 (enExample) | ||
| JP2008518900A5 (enExample) | ||
| JP2008063336A5 (enExample) | ||
| US20150175508A1 (en) | Fluorination of aryl compounds | |
| Nair et al. | Nickel-catalysed fluoromethylation reactions | |
| JP2014520075A5 (enExample) | ||
| JP2016535033A5 (enExample) | ||
| JP2016539168A5 (enExample) | ||
| JP6419092B2 (ja) | ビピリジル化合物 | |
| JP2016040296A5 (enExample) | ||
| Ishida et al. | Synthesis of Azaaromatic Borane Intramolecular Complexes by Palladium‐Catalyzed Reaction of Azaaromatic Halides with Alkynyl (triaryl) borates | |
| CN106554325B (zh) | 一种手性苯并磺酰胺类化合物的制备方法 | |
| Kano et al. | Stereoselective synthesis of cyclic amino acids via asymmetric phase-transfer catalytic alkylation | |
| JP2017513885A5 (enExample) | ||
| JP2015512436A5 (enExample) | ||
| JP2011506323A5 (enExample) | ||
| JP2011079866A5 (enExample) | ||
| JP2012530113A5 (enExample) | ||
| JP2007204383A5 (enExample) |